Prof. Dr. Martin Fromm

Lehrstuhl für Klinische Pharmakologie und Klinische Toxikologie

Documentation of Drug-Related Problems with ICD-11: Application of the New WHO Code-Set to Clinical Routine Data (2023) Andrikyan W, Jung-Poppe L, Altenbuchner A, Nicolaus HF, Pfistermeister B, Dormann H, Fromm M, Maas R Journal article, Original article Cancer-Type Organic Anion Transporting Polypeptide 1B3 Is Localized in Lysosomes and Mediates Resistance against Kinase Inhibitors (2022) Haberkorn B, Oswald S, Kehl N, Geßner A, Taudte V, Dobert J, Zunke F, et al. Journal article Characteristics and Cost of Unscheduled Hospitalizations in Patients Treated with New Oral Anticancer Drugs in Germany: Evidence from the Randomized AMBORA Trial (2022) Dürr P, Meier F, Schlichtig K, Schramm A, Schötz L, Fromm M, Dörje F Journal article Psychopharmakologische Behandlung von Menschen mit schwerer Demenz (2022) Diehl K, Kratzer A, Donath C, Maas R, Fromm M, Kornhuber J, Grässel E Journal article POLAR-POLypharmacy, drug interActions and Risks-how can data from inpatient care support their assessment? (2022) Scherag A, Andrikyan W, Dreischulte T, Dürr P, Fromm M, Gewehr J, Jaehde U, et al. Journal article Propionate induced bacterial-derived histamine promotes resolution of synovial inflammation (2022) Dürholz K, Lucas S, Schmid E, Schaelter F, Frech M, Azizov V, Hofmann J, et al. Conference contribution Drug Therapy Safety with new oral Antitumor Agents for the Therapy of Prostate and Renal Cell Carcinoma: Findings from the AMBORA Study (2022) Cuba L, Schlichtig K, Dürr P, Bellut L, Meidenbauer N, Kunath F, Goebell P, et al. Conference contribution Arzneimittelmerkblätter und weitere Informationsmaterialien bei oraler Tumortherapie (2022) Dörje F, Fromm M Journal article MATE1 Deficiency Exacerbates Dofetilide-Induced Proarrhythmia (2022) Uddin ME, Eisenmann ED, Li Y, Huang KM, Garrison DA, Talebi Z, Gibson AA, et al. Journal article New Oral Antitumor Drugs and Medication Safety in Uro-Oncology: Implications for Clinical Practice Based on a Subgroup Analysis of the AMBORA Trial (2022) Schlichtig K, Cuba L, Dürr P, Bellut L, Meidenbauer N, Kunath F, Goebell P, et al. Journal article